Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

DESVENLAFAXINE SUCCINATE Drug Profile

« Back to Dashboard

Which patents cover Desvenlafaxine Succinate, and when can generics launch?

Desvenlafaxine Succinate is a drug marketed by Alembic Pharms Ltd, Sandoz Inc, Actavis Labs Fl Inc, Lupin Ltd, West-ward Pharms Int, and Mylan Pharms Inc. and is included in seven NDAs.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for Tradename: DESVENLAFAXINE SUCCINATE

Patents:0
Applicants:6
NDAs:7
Suppliers / Packagers: see list6
Clinical Trials: see list62
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DESVENLAFAXINE SUCCINATE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic Pharms Ltd
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204003-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
Actavis Labs Fl Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204065-003Jul 29, 2016ABRXNoNo► Subscribe► Subscribe
Sandoz Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204028-002Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204095-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
Lupin Ltd
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204172-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Formulary management
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot